ArticleCell biochemistry and biophysics2026
From Forest Floor to Therapeutic Candidate: Amanita princeps Corner & Bas, 1962 Counters Visceral Leishmaniasis via the NO-Arginase Axis and Mitochondrial Pathway.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Visceral leishmaniasis (VL), caused by Leishmania donovani, is one of the most lethal parasitic diseases, causing 30000 deaths annually. Pentavalent antimonials, with limited effectiveness, cytotoxicity, drug resistance, and therapeutic limitations, underscore the urgent need for the development of novel, selective, and cost-effective antileishmanial agents. The Indian pharmaceutical industry, a major global economic sector, is showing growing interest in mushrooms in developing alternative drugs against several diseases. Thus, this study focuses on the antileishmanial potential of the hydroalcoholic extract of Amanita princeps, a wild edible mushroom, with detailed mechanistic analysis. In our research, the cell-inhibitory activity of the extract was evaluated by the MTT assay against promastigotes, axenic amastigotes, and intracellular amastigotes, yielding IC₅₀ values of 21.20, 30.26, and 38.93 μg/mL, respectively, with high selectivity indices (>10). A detailed mechanistic study revealed that the extract can disrupt the NO-arginase axis, suppress antioxidant enzymes (SOD and catalase), and elevate lipid peroxidation, ultimately causing intracellular oxidative stress. Further, flow cytometric and fluorescence microscopic study confirmed elevated reactive oxygen species, mitochondrial membrane depolarization, nuclear fragmentation, sub-G0/G1 cell cycle arrest, leading towards apoptosis as evidenced by AO/EtBr dual staining. Furthermore, the extract was able to restore host immunological balance by upregulating pro-inflammatory cytokines (IL-12β, TNF-α) and suppressing anti-inflammatory mediators (IL-10, TGF-β). Finally, GC-MS, network pharmacological and molecular docking study identified Urs-12-en-28-ol, a ursane triterpenoid with the highest affinity against DHFR (-9.7 kcal/mol) and demonstrated significant in vitro antileishmanial activity. Conclusively, our findings establish Amanita princeps as a promising candidate for next-generation antileishmanial drug development.
Indexed as
Identifiers
42758438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.